(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find Unexpected, yet invaluable treasure Excursion Rentals - 2Vote In favor of Your Favored Sort Of Dress
- 3Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- 4Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- 5Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Vote In favor of Your Favored Kind Of Attire
- Sentimental tree to shine at Arctic League annual broadcast
- Single women risk rape and exploitation in search for better life in Europe
- 5 Chiefs That Changed Our Opinion on Film
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Instructions to Decide the Best SUV Size for Seniors
- Zelensky names spy chief to head presidential office after corruption row
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Which Brilliant Home Gadget Can't You Reside Without?
